ALSO NOTED: Novasite buys PsyCheNomicS; AstraZeneca fined; Corixa shareholder balks at buyout; and much more...

> San Diego-based Novasite has acquired PsyCheNomicS for an undisclosed amount. PsyCheNomicS has been developing treatments for the central nervous system. Release

> AstraZeneca has been fined £40 million by the European Commission for blocking generic versions of Prilosec. Article

> A major shareholder of Corixa says it will vote against GlaxoSmithKline's proposed acquisition, saying the bid was undervalued. Release

> The FDA has approved an expansion of the Angiomax label for more types of angioplasty procedures. Story

> Houston-based Fabre-Kramer has reacquired the rights to Gepirone ER, a once-daily product being developed for the treatment of depression. Release

> Spectrum Pharmaceuticals says the FDA has approved its generic version of Bristol-Myers Squibb's Paraplatin. Article

> The proposed merger between Genzyme and Bone Care International has cleared the FTC. Release

And Finally... Hundreds of doctors have taken the pledge on to shun drug companies' freebies. Story

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.